Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
P/B ratio for Novavax, Inc. (NVAX)
P/B ratio as of 2023: -0.67
According to Novavax, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.67. At the end of 2022 the company had a P/B ratio of -1.27.
P/B ratio history for Novavax, Inc. from 1996 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -0.67 |
| 2022 | -1.27 |
| 2021 | -30.27 |
| 2020 | 10.23 |
| 2019 | -0.52 |
| 2018 | -4.05 |
| 2017 | -3.57 |
| 2016 | -61.52 |
| 2015 | 7.52 |
| 2014 | 5.83 |
| 2013 | 4.27 |
| 2012 | 3.10 |
| 2011 | 2.66 |
| 2010 | 4.31 |
| 2009 | 3.06 |
| 2008 | 2.83 |
| 2007 | 3.23 |
| 2006 | 2.56 |
| 2005 | 3.32 |
| 2004 | 3.62 |
| 2003 | 4.98 |
| 2002 | 7.87 |
| 2001 | 11.63 |
| 2000 | 5.08 |
| 1999 | 29.15 |
| 1998 | 8.03 |
| 1997 | 8.97 |
| 1996 | 6.83 |